Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in hypermutated/ultramutated endometrial cancer
NCT02899793Phase 2Completed
- Sponsor
- Yale University
- Start
- Sep 2016
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in endometrial cancer (EC), sponsored by Yale University. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT02899793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02899793.